BD-1047 dihydrobromide is primarily used in research settings to study the sigma-1 receptor, a protein implicated in various neurological and psychiatric conditions. It acts as a selective antagonist for sigma-1 receptors, making it a valuable tool for understanding the receptor's role in cellular processes and disease mechanisms. Researchers utilize it to explore its potential in modulating neuroprotection, pain management, and addiction behaviors. Additionally, it aids in investigating the receptor's involvement in conditions like depression, schizophrenia, and neurodegenerative diseases such as Alzheimer's. Its application extends to preclinical studies aimed at developing novel therapeutic strategies targeting sigma-1 receptors.